Aspen

Aspen Close to Covid Vaccine License Deal with J&J

South Africa's Aspen Pharmacare aims to ramp up its Covid-19 vaccine manufacturing capacity to 1.3 billion doses per year by February 2024, from 250 to 300 million doses at present, the company has said.

Mylan Buys Aspen’s European Thrombosis Assets

Mylan has agreed to buy the related intellectual property and commercialization rights of Aspen Pharmacare’s European thrombosis business for €641.9 million. The company will use proceeds from the sale to pay down debt.

AstraZeneca Sells Anesthetics Rights to Aspen

EU Investigates Aspen for Price Gouging

BASF and Aspen Aerogels Expand Partnership

GlaxoSmithKline Sells Australian Drugs to Aspen for $270 Million